Absci Corporation

Contributing Author

Recent Articles by Absci Corporation

Jul-14	Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026 ABSI GlobeNewswire
Jun-24	Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors ABSI +35.96% GlobeNewswire
Jun-24	Absci Announces Positive Interim Phase 1 Data from the HEADLINE Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) ABSI +35.96% GlobeNewswire
May-20	Absci to Participate in Upcoming Investor Conferences ABSI +6.91% GlobeNewswire
May-07	Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results ABSI GlobeNewswire
May-04	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ABSI GlobeNewswire
Apr-23	Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026 ABSI +7.88% GlobeNewswire
Apr-08	Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference ABSI GlobeNewswire
Mar-24	Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results ABSI GlobeNewswire
Mar-24	Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic ABSI GlobeNewswire
Mar-06	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ABSI -8.11% ABSI +5.46% GlobeNewswire
Mar-03	Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer ABSI -8.21% GlobeNewswire
Feb-24	Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 ABSI GlobeNewswire
Feb-17	Absci to Participate in Upcoming Investor Conferences ABSI GlobeNewswire
Dec-16	Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference ABSI GlobeNewswire
Dec-11	Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201 Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization ABSI GlobeNewswire
Dec-10	Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research ABSI +12.78% GlobeNewswire
Dec-04	Absci Announces First Participants Dosed in Phase 1/2a HEADLINE Trial of AI-Designed Antibody ABS-201 for Androgenetic Alopecia ABSI +13.37% GlobeNewswire
Nov-12	Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results ABSI ABSI -22.35% GlobeNewswire
Oct-29	Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025 ABSI ABSI -6.41% GlobeNewswire
Oct-27	Absci to Participate in Upcoming Investor Conferences ABSI +5.39% GlobeNewswire
Oct-15	Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial ABSI +28.21% GlobeNewswire
Aug-25	Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg ABSI GlobeNewswire
Aug-20	Absci to Participate in Upcoming Investor Conferences ABSI GlobeNewswire
Aug-12	Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results ABSI ABSI +5.05% GlobeNewswire
Aug-07	Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target ABSI GlobeNewswire
Jul-30	Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025 ABSI GlobeNewswire
Jul-24	Absci Announces Pricing of Public Offering of Common Stock ABSI -17.66% GlobeNewswire
Jul-24	Absci Announces Proposed Public Offering of Common Stock ABSI ABSI -17.66% GlobeNewswire
Jul-07	Absci Appoints Biopharma Leader Mary Szela to Board of Directors ABSI -6.86% GlobeNewswire
May-20	Absci to Participate in Upcoming Investor Conferences ABSI GlobeNewswire
May-13	Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results ABSI GlobeNewswire
May-13	Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease ABSI GlobeNewswire

Absci Corporation

Recent Articles by Absci Corporation

Upgrade your Finviz experience